孟加拉国男子患罕见病 手脚增生如树根

2016-02-01 佚名 腾讯新闻

孟加拉国人Abul Bajandar患有一种罕见的皮肤病。他的手和脚长出像树根一样的疣状增生,就像一个“树人”。        Abul Bajandar来自孟加拉国库尔纳,患有这种名为“疣状表皮发育不良症”已经近7年。         达卡医学院附属医院准备建立一个



孟加拉国人Abul Bajandar患有一种罕见的皮肤病。他的手和脚长出像树根一样的疣状增生,就像一个“树人”。  
   
 Abul Bajandar来自孟加拉国库尔纳,患有这种名为“疣状表皮发育不良症”已经近7年。  
    
 达卡医学院附属医院准备建立一个医疗委员会,为他制定治疗计划。  
   
 Abul Bajandar手上的增生。  
   
 他的脚上同样有这种疣状增生,程度比双手稍轻。  
 
  
 Abul Bajandar躺在医院的床上,等待医生检查。              
  英国每日邮报网站相关报道(英文) 

 

  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009649, encodeId=24232009649e9, content=<a href='/topic/show?id=a3e845384ae' target=_blank style='color:#2F92EE;'>#孟加拉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45384, encryptionId=a3e845384ae, topicName=孟加拉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 10 15:28:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467114, encodeId=5f8a146e1144f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486279, encodeId=1b7314862e933, content=<a href='/topic/show?id=a10745385e9' target=_blank style='color:#2F92EE;'>#孟加拉国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45385, encryptionId=a10745385e9, topicName=孟加拉国)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06948104014, createdName=ms4657536712156177, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62693, encodeId=1be0626930a, content=太罕见了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62694, encodeId=bdc262694bb, content=希望有办法, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=)]
    2016-03-10 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009649, encodeId=24232009649e9, content=<a href='/topic/show?id=a3e845384ae' target=_blank style='color:#2F92EE;'>#孟加拉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45384, encryptionId=a3e845384ae, topicName=孟加拉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 10 15:28:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467114, encodeId=5f8a146e1144f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486279, encodeId=1b7314862e933, content=<a href='/topic/show?id=a10745385e9' target=_blank style='color:#2F92EE;'>#孟加拉国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45385, encryptionId=a10745385e9, topicName=孟加拉国)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06948104014, createdName=ms4657536712156177, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62693, encodeId=1be0626930a, content=太罕见了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62694, encodeId=bdc262694bb, content=希望有办法, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=)]
    2016-02-03 syscxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009649, encodeId=24232009649e9, content=<a href='/topic/show?id=a3e845384ae' target=_blank style='color:#2F92EE;'>#孟加拉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45384, encryptionId=a3e845384ae, topicName=孟加拉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 10 15:28:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467114, encodeId=5f8a146e1144f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486279, encodeId=1b7314862e933, content=<a href='/topic/show?id=a10745385e9' target=_blank style='color:#2F92EE;'>#孟加拉国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45385, encryptionId=a10745385e9, topicName=孟加拉国)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06948104014, createdName=ms4657536712156177, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62693, encodeId=1be0626930a, content=太罕见了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62694, encodeId=bdc262694bb, content=希望有办法, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2009649, encodeId=24232009649e9, content=<a href='/topic/show?id=a3e845384ae' target=_blank style='color:#2F92EE;'>#孟加拉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45384, encryptionId=a3e845384ae, topicName=孟加拉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 10 15:28:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467114, encodeId=5f8a146e1144f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486279, encodeId=1b7314862e933, content=<a href='/topic/show?id=a10745385e9' target=_blank style='color:#2F92EE;'>#孟加拉国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45385, encryptionId=a10745385e9, topicName=孟加拉国)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06948104014, createdName=ms4657536712156177, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62693, encodeId=1be0626930a, content=太罕见了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62694, encodeId=bdc262694bb, content=希望有办法, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=)]
    2016-02-02 李继凯

    太罕见了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2009649, encodeId=24232009649e9, content=<a href='/topic/show?id=a3e845384ae' target=_blank style='color:#2F92EE;'>#孟加拉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45384, encryptionId=a3e845384ae, topicName=孟加拉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Mar 10 15:28:00 CST 2016, time=2016-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467114, encodeId=5f8a146e1144f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486279, encodeId=1b7314862e933, content=<a href='/topic/show?id=a10745385e9' target=_blank style='color:#2F92EE;'>#孟加拉国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45385, encryptionId=a10745385e9, topicName=孟加拉国)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06948104014, createdName=ms4657536712156177, createdTime=Wed Feb 03 00:28:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62693, encodeId=1be0626930a, content=太罕见了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62694, encodeId=bdc262694bb, content=希望有办法, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Feb 02 01:02:00 CST 2016, time=2016-02-02, status=1, ipAttribution=)]
    2016-02-02 李继凯

    希望有办法

    0

相关资讯

好消息!浙江将渐冻症等罕见病纳入医疗保障

为了帮助群众化解巨额灾难性医疗费用支出风险,浙江省结合医保基金结余和罕见病发病诊治等情况,决定将部分罕见病纳入医疗保障范畴,进一步遏制因病致贫、因病返贫。浙江省人力社保厅、省民政厅、省财政厅、省卫生计生委联合发出的《关于加强罕见病医疗保障工作的通知》指出,自2016年1月1日起戈谢病、渐冻症、苯丙酮尿症列入罕见病医疗保障病种范围。据了解,保障对象包括现参加省基本医保并获得浙江户籍满5年的患者;或参

Nature:英国万人基因组计划揭示罕见突变与人类疾病关系

近日,著名国际学术期刊Nature刊登了迄今为止最大的人群基因组测序研究,而关于这些数据的来源和用途也同一时间发表在了Nature, Nature Genetics, Bioinformatics以及Nature Communication等Nature系列杂志上。罕见基因突变是DNA中携带的遗传变化,而在一个人群中携带这种突变的人相对较少。英国的万人研究就是为了探究罕见遗传突变与人类疾病和疾病风

罕见病救助:“青岛模式”带给我们的思考与启示

引言:去年盛夏,"冰桶挑战"的火热,让"罕见病"这个在国内还不被大众所了解的领域,在近一年时间内频频进入公众视野。据国内医学界估算,在我国有超过1600多万的各类罕见病患者,这是一个不可忽视的庞大社会群体。随着国内经济、文化的快速发展,居民对生活质量的追求,对健康的期望,对享有医疗保障的需要,已越来越高。罕见病领域所面临的问题,已成了国家精神文明建设,创建社会和谐家园,实现伟大"中国梦"征途上

不孤独的孤儿药(下篇):孤独在中国

和欧美孤儿药研发火爆现状截然不同,目前我国的孤儿药研发和欧美相比实在是冰火两重天,中国本土自主研发成功的孤儿药微乎其微,深圳微芯的西达苯胺算是一个罕见的亮点,今年年初获批上市的首个适应症是复发及难治性外周T细胞淋巴瘤,是中国首个授权美国等发达国家专利使用的原创新药。由于像西达苯胺这样用于治疗罕见病的中国本土孤儿药比罕见病本身要罕见的多,所以中国患者和家属只能期待国外药品公司在中国尽快获得罕

我国罕见病治疗诊断现状

不久前风靡一时的"挑战冰桶",让社会大众开始逐渐关注到了渐冻人、瓷娃娃等罕见病群体。罕见病是指那些患病率较低的疾病,又称"孤儿病"。 根据世界卫生组织(WHO)的定义,罕见病为患病人数占总人口的0.65‰~1‰的疾病。世界各国根据自己国家的具体情况,对罕见病的认定标准存在一定的差异。例如,美国将罕见病定义为每年患病人数少于20万人(或发病人口比例小于1/1500)的疾病;日本规定,罕见病为患病

JAMA:罕见病诊断的新思路

罕见病的诊断和治疗一直都是难题,而测序技术的出现则带来了一丝曙光。一般来说,患者出现一些症状后,通常先看医生,然后开展外显子组测序,并借助研究人员,找到分子机制。然而,根据《美国医学会杂志》(JAMA)上的一篇文章,这个顺序现在反过来了。文章讲述了一个荷兰男孩的故事。他叫Vincent Pieterse,出生在2002年底。在婴儿时期,他似乎很健康,不过随着他渐渐长大,出现了学习障碍、轻微自闭症、